# Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib

> **NCT01514448** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 29 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma (mRCC)

## Interventions

- **DRUG:** Everolimus (RAD001)

## Key facts

- **NCT ID:** NCT01514448
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-21
- **Primary completion:** 2016-04-01
- **Final completion:** 2016-04-01
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2017-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01514448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01514448, "Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01514448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*